Converting Escherichia coli into an archaebacterium with a hybrid heterochiral membrane
One of the main differences between bacteria and archaea concerns their membrane composition. Whereas bacterial membranes are made up of glycerol-3-phosphate ester lipids, archaeal membranes are composed of glycerol-1-phosphate ether lipids. Here, we report the construction of a stable hybrid hetero...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 115; no. 14; pp. 3704 - 3709 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
03.04.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | One of the main differences between bacteria and archaea concerns their membrane composition. Whereas bacterial membranes are made up of glycerol-3-phosphate ester lipids, archaeal membranes are composed of glycerol-1-phosphate ether lipids. Here, we report the construction of a stable hybrid heterochiral membrane through lipid engineering of the bacterium Escherichia coli. By boosting isoprenoid biosynthesis and heterologous expression of archaeal ether lipid biosynthesis genes, we obtained a viable E. coli strain of which the membranes contain archaeal lipids with the expected stereochemistry. It has been found that the archaeal lipid biosynthesis enzymes are relatively promiscuous with respect to their glycerol phosphate backbone and that E. coli has the unexpected potential to generate glycerol-1-phosphate. The unprecedented level of 20–30% archaeal lipids in a bacterial cell has allowed for analyzing the effect on the mixed-membrane cell’s phenotype. Interestingly, growth rates are unchanged, whereas the robustness of cells with a hybrid heterochiral membrane appeared slightly increased. The implications of these findings for evolutionary scenarios are discussed. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 2Present address: Department of Medicine, Section of Infectious Diseases, Boston University School of Medicine, Boston, MA 02118. Edited by Eugene V. Koonin, National Institutes of Health, Bethesda, MD, and approved February 27, 2018 (received for review December 12, 2017) 1A.C. and M.F.S. contributed equally to this work. Author contributions: A.C., M.F.S., S.W.M.K., A.J.M., A.J.M.D., and J.v.d.O. designed research; A.C., M.F.S., M.E., S.J., V.R.J., R.L.H.A., and J.v.d.O. performed research; A.J.M. contributed new reagents/analytic tools; A.C., M.F.S., S.W.M.K., A.J.M., A.J.M.D., and J.v.d.O. analyzed data; and A.C., M.F.S., S.W.M.K., A.J.M.D., and J.v.d.O. wrote the paper. |
ISSN: | 0027-8424 1091-6490 |
DOI: | 10.1073/pnas.1721604115 |